Role of IGF-1 in glucose regulation and cardiovascular disease

References

• Wilson PW. Diabetes mellitus and coronary heart disease. Am. J. Kidney Dis.32(5 Suppl. 3), S89–S100 (1998).
   Google Scholar
• Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am. J. Cardiol.54(7), 718–721 (1984).
   PubMedGoogle Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16(2), 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Cubbon RM, Wheatcroft SB, Grant PJ et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur. Heart J. 28(5), 540–545 (2007).
   PubMed Web of Science ®Google Scholar
• Cubbon RM, Gale CP, Rajwani A et al. Aspirin and mortality in patients with diabetes mellitus sustaining acute coronary syndrome. Diabetes Care31(2), 363–365 (2007).
   PubMedGoogle Scholar
• Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr. Rev.28(5), 463–491 (2007).
   PubMed Web of Science ®Google Scholar
• Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev.21(12), 1443–1455 (2007).
   PubMed Web of Science ®Google Scholar
• Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA263(21), 2893–2898 (1990).
   PubMed Web of Science ®Google Scholar
• Bartnik M, Norhammar A, Ryden L. Hyperglycaemia and cardiovascular disease. J. Intern. Med.262(2), 145–156 (2007).
   PubMed Web of Science ®Google Scholar
• Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab. Vasc. Dis. Res.4(2), 84–88 (2007).
   PubMedGoogle Scholar
• Jansson PA. Endothelial dysfunction in insulin resistance and Type 2 diabetes. J. Intern. Med.262(2), 173–183 (2007).
   PubMed Web of Science ®Google Scholar
• Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab.3(1), 46–56 (2007).
   PubMedGoogle Scholar
• Grant PJ. Diabetes mellitus as a prothrombotic condition. J. Intern. Med.262(2), 157–172 (2007).
   PubMed Web of Science ®Google Scholar
• Daughaday WH , Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr. Rev.10, 68–91 (1989).
   PubMed Web of Science ®Google Scholar
• Avruch J. Insulin and amino-acid regulation of mTOR signalling and kinase activity through the Rheb GTPase. Oncogene25, 6361–6372 (2006).
   PubMed Web of Science ®Google Scholar
• Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N. Engl. J. Med.336(9), 633–640 (1997).
   PubMed Web of Science ®Google Scholar
• Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr. Relat. Cancer1, 533–543 (2006).
   Google Scholar
• De Meyts P. Role of time factor in signalling specificity: application to mitogenic and metabolic signalling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. Metabolism44, 2–11 (1995).
   PubMed Web of Science ®Google Scholar
• Clemmons D. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr. Opin. Pharmacol.6(6), 620–625 (2006).
   PubMed Web of Science ®Google Scholar
• Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK. Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J. Clin. Invest.81(4), 976–981 (1988).
   PubMed Web of Science ®Google Scholar
• Nitert MD, Chisalita SI, Olsson K, Bornfeldt KE, Arnqvist HJ. IGF-I/insulin hybrid receptors in human endothelial cells. Mol. Cell. Endocrinol.229(1–2), 31–37 (2005).
   PubMedGoogle Scholar
• Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem. J. 290(Pt 2), 419–426 (1993).
   PubMed Web of Science ®Google Scholar
• Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem. J. 327(Pt 1), 209–215 (1997).
   PubMed Web of Science ®Google Scholar
• Li G, Barrett EJ, Wang H, Chai W, Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology146(11), 4690–4696 (2005).
   PubMed Web of Science ®Google Scholar
• Federici M, Porzio O, Lauro D et al. Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity. J. Clin. Endocrinol. Metab.83(8), 2911–2915 (1998).
   PubMed Web of Science ®Google Scholar
• Federici M, Porzio O, Zucaro L et al. Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Mol. Cell Endocrinol.135(1), 41–47 (1997).
   PubMed Web of Science ®Google Scholar
• Blakesley VA, Scrimgeour A, Esposito D, Le Roith D. Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine Growth Factor Rev.7(2), 153–159 (1996).
   PubMedGoogle Scholar
• Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int.45(2), 598–604 (1994).
   PubMed Web of Science ®Google Scholar
• Klip A, Paquet MR. Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care13(3), 228–243 (1990).
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med.340(2), 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabetic Medicine20(4), 255–268 (2003).
   PubMed Web of Science ®Google Scholar
• Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am. J. Cardiol.92(4A), 10J-17J (2003).
   PubMed Web of Science ®Google Scholar
• Abe H, Yamada N, Kamata K et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J. Clin. Invest.101(8), 1784–1788 (1998).
   PubMed Web of Science ®Google Scholar
• Katakam PV, Ujhelyi MR, Hoenig ME, Miller AW. Endothelial dysfunction precedes hypertension in diet-induced insulin resistance. Am. J. Physiol.275(3 Pt 2), R788–R792 (1998).
   PubMed Web of Science ®Google Scholar
• Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors in the fed and fasted states. J. Clin. Endocrinol. Metab.55, 999–1002 (1982).
   PubMed Web of Science ®Google Scholar
• Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm. Res.42(4–5), 145–151 (1994).
   PubMed Web of Science ®Google Scholar
• Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N. Engl. J. Med.317(3), 137–140 (1987).
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev.16(1), 3–34 (1995).
   PubMed Web of Science ®Google Scholar
• Cusi K, DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in Type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J. Clin. Endocrinol. Metab.85(9), 3077–3084 (2000).
   PubMed Web of Science ®Google Scholar
• Holt RI, Simpson HL, Sonksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet. Med.20(1), 3–15 (2003).
   PubMedGoogle Scholar
• O’ Connell T, Clemmons DR. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J. Clin. Endocrinol. Metab.87(9), 4356–4360 (2002).
   PubMedGoogle Scholar
• Yakar S. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J. Clin. Invest.113, 96–105 (2004).
   PubMed Web of Science ®Google Scholar
• Dohm GL, Elton CW, Raju MS et al. IGF-I-stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes39(9), 1028–1032 (1990).
   PubMedGoogle Scholar
• Fernandez AM, Kim JK, Yakar S et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes Type 2 diabetes. Genes. Dev.15(15), 1926–1934 (2001).
   PubMedGoogle Scholar
• Pennisi P, Gavrilova O, Setser-Portas J et al. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of Type 2 diabetes mellitus. Endocrinology147(6), 2619–2630 (2006).
   PubMedGoogle Scholar
• Chang PY, Benecke H, Marchand-Brustel Y, Lawitts J, Moller DE. Expression of a dominant-negative mutant human insulin receptor in the muscle of transgenic mice. J. Biol. Chem.269(23), 16034–16040 (1994).
   PubMedGoogle Scholar
• Chen YH, Hung PF, Kao YH. IGF-I downregulates resistin gene expression and protein secretion. Am. J. Physiol. Endocrinol. Metab.288(5), E1019–E1027 (2005).
   Google Scholar
• Accili D. Lilly lecture 2003: the struggle for mastery in insulin action: from triumvirate to republic. Diabetes53(7), 1633–1642 (2004).
   PubMed Web of Science ®Google Scholar
• Van Schravendijk CF, Foriers A, Van den Brande JL, Pipeleers DG. Evidence for the presence of Type I insulin-like growth factor receptors on rat pancreatic A and B cells. Endocrinology121(5), 1784–1788 (1987).
   PubMed Web of Science ®Google Scholar
• van Haeften TW , Twickler TB. Insulin-like growth factors and pancreas β cells. Eur. J. Clin. Invest.34(4), 249–255 (2004).
   PubMed Web of Science ®Google Scholar
• Rhodes CJ. IGF-I and GH post-receptor signaling mechanisms for pancreatic β-cell replication. J. Mol. Endocrinol.24(3), 303–311 (2000).
   PubMed Web of Science ®Google Scholar
• Liu JL. Does IGF-I stimulate pancreatic islet cell growth? Cell Biochem. Biophys.48(2–3), 115–125 (2007).
   PubMedGoogle Scholar
• Lu Y, Herrera PL, Guo Y et al. Pancreatic-specific inactivation of IGF-I gene causes enlarged pancreatic islets and significant resistance to diabetes. Diabetes53(12), 3131–3141 (2004).
   PubMed Web of Science ®Google Scholar
• Xuan S, Kitamura T, Nakae J et al. Defective insulin secretion in pancreatic {β} cells lacking Type 1 IGF receptor. J. Clin. Invest.110(7), 1011–1019 (2002).
   PubMed Web of Science ®Google Scholar
• Kulkarni RN, Holzenberger M, Shih DQ et al. β-cell-specific deletion of the IGF1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter β-cell mass. Nat. Genet.31(1), 111–115 (2002).
   PubMed Web of Science ®Google Scholar
• Ueki K, Okada T, Hu J et al. Total insulin and IGF-I resistance in pancreatic β cells causes overt diabetes. Nat. Genet.38(5), 583–588 (2006).
   PubMedGoogle Scholar
• Entingh-Pearsall A, Kahn CR. Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J. Biol. Chem.279(36), 38016–38024 (2004).
   PubMed Web of Science ®Google Scholar
• Clauson PG, Brismar K, Hall K, Linnarsson R, Grill V. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of Type 2 diabetic patients in Sweden. Scand. J. Clin. Lab. Invest.58(4), 353–360 (1998).
   PubMed Web of Science ®Google Scholar
• Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of Type 2 diabetes. Diabetes Metab. Res. Rev.15(5), 314–322 (1999).
   PubMed Web of Science ®Google Scholar
• Nam SY, Lee EJ, Kim KR et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int. J. Obes. Relat. Metab. Disord.21(5), 355–359 (1997).
   PubMed Web of Science ®Google Scholar
• Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet359(9319), 1740–1745 (2002).
   PubMed Web of Science ®Google Scholar
• Tan K , Baxter RC. Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age. J. Clin. Endocrinol. Metab.63(3), 651–655 (1986).
   PubMedGoogle Scholar
• Moses AC, Young SC, Morrow LA, O’Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in Type II diabetes. Diabetes45(1), 91–100 (1996).
   PubMed Web of Science ®Google Scholar
• Jabri N, Schalch DS, Schwartz SL et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant Type II diabetic patients. Diabetes43(3), 369–374 (1994).
   PubMed Web of Science ®Google Scholar
• Carroll PV, Christ ER, Umpleby AM et al. IGF-I treatment in adults with Type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic–euglycemic amino acid clamp. Diabetes49(5), 789–796 (2000).
   PubMedGoogle Scholar
• Morrow LA, O’Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the Type A syndrome of severe insulin resistance. J. Clin. Endocrinol. Metab.79(1), 205–210 (1994).
   PubMed Web of Science ®Google Scholar
• Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet350(9086), 1199–1204 (1997).
   PubMed Web of Science ®Google Scholar
• Boulware SD, Tamborlane WV, Rennert NJ et al. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J. Clin. Invest.93(3), 1131–1139 (1994).
   PubMed Web of Science ®Google Scholar
• Zenobi PD, Jaeggi-Groisman SE, Riesen WF et al. Insulin-like growth factor-I improves glucose and lipid metabolism in Type 2 diabetes mellitus. J. Clin. Invest.90(6), 2234–2241 (1992).
   PubMed Web of Science ®Google Scholar
• Kuzuya H. Trial of insulin like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes42, 696–705 (1999).
   Google Scholar
• RH in NIDDM Study Group. Evidence from a dose ranging study that recombinant insulin-like growth factor-1 (RhIGF-1) effectively and safely improves glycaemic control in non-insulin dependent diabetes mellitus. Diabetes45 (Suppl. 2), 27A (1996).
   PubMed Web of Science ®Google Scholar
• Schwartz SL. RHIGF1 co-therapy with Insulin Subgroup. RHIGF1 improves glucose control in insulin requiring Type 2 diabetes. Proceedings of the 5th Annual Meeting of the American Diabetes Association, San Antonio, Texas, USA, 582 (1997).
   Google Scholar
• Hussain MA, Schmitz O, Mengel A et al. Insulin-like growth factor-I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J. Clin. Invest.92(5), 2249–2256 (1993).
   PubMed Web of Science ®Google Scholar
• O’Connor R, Fennelly C, Krause D. Regulation of survival signals from the insulin-like growth factor-I receptor. Biochem. Soc. Trans.28, 47–15 (2000).
   PubMed Web of Science ®Google Scholar
• Probst-Hensch NM. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br. J. Cancer85, 1695–1699 (2001).
   PubMed Web of Science ®Google Scholar
• Hankinson SE. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet351, 1393–1396 (1998).
   PubMed Web of Science ®Google Scholar
• Yu H. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case–control analysis. J. Natl Cancer Inst.91, 151–156 (1999).
   PubMed Web of Science ®Google Scholar
• Chan JM. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science279, 563–566 (1998).
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Moses AC, Sommer A et al. RhIGF-I/rhIGFBP-3 administration to patients with Type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm. IGF Res.15(4), 265–274 (2005).
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Sleevi M, Allan G, Sommer A. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in Type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes. J. Clin. Endocrinol. Metab.92(7), 2652–2658 (2007).
   PubMed Web of Science ®Google Scholar
• Heald AH, Anderson SG, Ivison F, Laing I, Gibson JM, Cruickshank K. C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis170(1), 79–86 (2003).
   PubMed Web of Science ®Google Scholar
• Colao A, Spiezia S, Di Somma C et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J. Endocrinol. Invest.28(5), 440–448 (2005).
   PubMedGoogle Scholar
• Ruotolo G, Båvenholm P, Brismar K et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J. Am. Coll. Cardiol.35(3), 647–654 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson AM, Ryan MC, Boyle AJ. The novel role of C-reactive protein in cardiovascular disease: Risk marker or pathogen. Int. J. Cardiol.106(3), 291–297 (2006).
   PubMed Web of Science ®Google Scholar
• Kaushal K, Heald AH, Siddals KW et al. The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. Diabetes Care27(11), 2682–2688 (2004).
   PubMedGoogle Scholar
• Rajpathak SN, McGinn AP, Strickler HD et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm. IGF Res.18(2), 166–173 (2007).
   PubMedGoogle Scholar
• Du J , Delafontaine P. Inhibition of vascular smooth muscle cell growth through antisense transcription of a rat insulin-like growth factor I receptor cDNA. Circ. Res.76(6), 963–972 (1995).
   PubMedGoogle Scholar
• Arnqvist HJ, Bornfeldt KE, Chen Y, Lindstrom T. The insulin-like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. Metabolism44, 58–66 (1995).
   PubMed Web of Science ®Google Scholar
• Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J. Clin. Invest.95(5), 2266–2274 (1995).
   PubMed Web of Science ®Google Scholar
• Johansson GS, Arnqvist HJ. Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells. Am. J. Physiol. Endocrinol. Metab.291(5), E1124–E1130 (2006).
   PubMed Web of Science ®Google Scholar
• Du J, Peng T, Scheidegger KJ, Delafontaine P. Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler. Thromb. Vasc. Biol.19, 2119–2126 (1999).
   PubMed Web of Science ®Google Scholar
• Brink M, Chrast J, Price SR, Mitch WE, Delafontaine P. Angiontensin II stimulates gene expression of cardiac insulin-like growth factor I and its receptor through effects on blood pressure and food intake. Hypertension34, 1053–1059 (1999).
   PubMedGoogle Scholar
• Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J. Clin. Invest.90, 439–446 (1992).
   PubMed Web of Science ®Google Scholar
• Li H, Dimayuga P, Yamashita M et al. Arterial injury in mice with severe insulin-like growth factor-1 (IGF-1) deficiency. J. Cardiovasc. Pharmacol. Ther.7(4), 227–233 (2002).
   PubMedGoogle Scholar
• Grant MB. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation89, 1511–1517 (1994).
   PubMed Web of Science ®Google Scholar
• Hayry P. Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 9, 1336–1344 (1995).
   PubMedGoogle Scholar
• Wang J. Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle α-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia. Endocrinology139, 2605–2614 (1998).
   PubMed Web of Science ®Google Scholar
• Eriksen UH, Amtorp O, Bagger JP et al. Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. Am. Heart J. 130(1), 1–8 (1995).
   PubMed Web of Science ®Google Scholar
• von Essen R, Ostermaier R, Grube E et al. Effects of octreotide treatment on restenosis after coronary angioplasty: results of the VERAS study. Verringerung der Restenoserate nach Angioplastie durch ein Somatostatin-analogon. Circulation96(5), 1482–1487 (1997).
   PubMed Web of Science ®Google Scholar
• Ling Y, Maile LA, Lieskovska J, Badley-Clarke J, Clemmons DR. Role of SHPS-1 in the regulation of insulin-like growth factor I-stimulated SHC and mitogen-activated protein kinase activation in vascular smooth muscle cells. Mol. Biol. Cell16, 3353–3364 (2005).
   PubMedGoogle Scholar
• Nichols TC. Reduction in atherosclerotic lesion size in pigs by αVα3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signalling. Circ. Res.85, 1040–1045 (1999).
   PubMedGoogle Scholar
• Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3K{α} pathway. Blood110(13), 4243–4252 (2007).
   PubMed Web of Science ®Google Scholar
• Kim S, Garcia A, Jackson SP, Kunapuli SP. Insulin-like growth factor-1 regulates platelet activation through PI3-K{α} isoform. Blood110(13), 4206–4213 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh MF, Barazi M, Pete G et al. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology137(5), 1798–1803 (1996).
   PubMed Web of Science ®Google Scholar
• Izhar U, Hasdai D, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron. Artery Dis.11(1), 69–76 (2000).
   PubMed Web of Science ®Google Scholar
• Tivesten A, Bollano E, Andersson I et al. Liver-derived insulin-like growth factor-I is involved in the regulation of blood pressure in mice. Endocrinology143(11), 4235–4242 (2002).
   PubMedGoogle Scholar
• Patel VA, Zhang QJ, Siddle K et al. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ. Res.88(9), 895–902 (2001).
   PubMedGoogle Scholar
• Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J. Mol. Cell Cardiol.33(10), 1777–1789 (2001).
   PubMedGoogle Scholar
• Bornfeldt KE, Arnqvist HJ, Dahlkvist HH, Skottner A, Wikberg JE. Receptors for insulin-like growth factor-I in plasma membranes isolated from bovine mesenteric arteries. Acta Endocrinol. (Copenh.)117(4), 428–434 (1988).
   PubMedGoogle Scholar
• Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest.83(5), 1774–1777 (1989).
   PubMed Web of Science ®Google Scholar
• Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl Acad. Sci. USA87(13), 5193–5197 (1990).
   PubMed Web of Science ®Google Scholar
• Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA88(11), 4651–4655 (1991).
   PubMed Web of Science ®Google Scholar
• Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl Acad. Sci. USA84(24), 9265–9269 (1987).
   PubMed Web of Science ®Google Scholar
• Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature327(6122), 524–526 (1987).
   PubMed Web of Science ®Google Scholar
• Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation93(7), 1331–1333 (1996).
   PubMed Web of Science ®Google Scholar
• Sowers JR. Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol.286(5), (2004).
   PubMedGoogle Scholar
• Schini-Kerth VB. Dual effects of insulin-like growth factor-I on the constitutive and inducible nitric oxide (NO) synthase-dependent formation of NO in vascular cells. J. Endocrinol. Invest.22(5 Suppl.), 82–88 (1999).
   PubMedGoogle Scholar
• Vecchione C, Colella S, Fratta L et al. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension37(6), 1480–1485 (2001).
   PubMedGoogle Scholar
• Haylor J, Singh I, el Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int.39(2), 333–335 (1991).
   PubMed Web of Science ®Google Scholar
• Copeland KC, Nair KS. Recombinant human insulin-like growth factor-I increases forearm blood flow. J. Clin. Endocrinol. Metab.79(1), 230–232 (1994).
   PubMed Web of Science ®Google Scholar
• Schmidt-Lucke C, Rössig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation111(22), 2981–2987 (2005).
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med.353(10), 999–1007 (2005).
   PubMed Web of Science ®Google Scholar
• Thum T, Hoeber S, Froese S et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ. Res.100(3), 434–443 (2007).
   PubMed Web of Science ®Google Scholar
• Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler. Thromb. Vasc. Biol.18(2), 277–282 (1998).
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab.89(1), 114–120 (2004).
   PubMed Web of Science ®Google Scholar
• Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case–control study. Circulation106, 939–944 (2002).
   PubMed Web of Science ®Google Scholar
• Goodman-Gruen D, Barrett-Connor E, Rosen C. IGF-1 and ischemic heart disease in older people. J. Am. Geriatr. Soc.48(7), 860–861 (2000).
   PubMedGoogle Scholar
• Conti E, Andreotti F, Sciahbasi A et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J. Am. Coll. Cardiol.38(1), 26–32 (2001).
   PubMed Web of Science ®Google Scholar
• Reeves I, Abribat T, Laramee P, Jasmin G, Brazeau P. Age-related serum levels of insulin-like growth factor-I, -II and IGF-binding protein-3 following myocardial infarction. Growth Horm. IGF Res.10(2), 78–84 (2000).
   PubMedGoogle Scholar
• Conti E, Andreotti F, Sestito A et al. Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am. J. Cardiol.89(8), 973–975 (2002).
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Hundborg HH, Sorensen HT et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J. Clin. Endocrinol. Metab.90(11), 5937–5941 (2005).
   PubMed Web of Science ®Google Scholar
• van den Beld AW, Bots ML, Janssen, Pols HAP, Lamberts SWJ, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am. J. Epidemiol.157(1), 25–31 (2003).
   PubMed Web of Science ®Google Scholar
• Spallarossa P, Brunelli C, Minuto F et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am. J. Cardiol.77(2), 200–202 (1996).
   PubMed Web of Science ®Google Scholar
• Kaplan RC, McGinn AP, Pollak MN et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J. Clin. Endocrinol. Metab.92(4), 1319–1325 (2007).
   PubMed Web of Science ®Google Scholar
• Vaessen N. A polymorphism in the gene for IGF1: functional properties and risk for Type 2 diabetes and myocardial infarction. Diabetes50, 637–642 (2001).
   PubMed Web of Science ®Google Scholar
• Ito H, Hiroe M, Hirata Y et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation87(5), 1715–1721 (1993).
   PubMed Web of Science ®Google Scholar
• Torella D, Rota M, Nurzynska D et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ. Res.94(4), 514–524 (2004).
   PubMed Web of Science ®Google Scholar
• Cittadini A, Ishiguro Y, Strömer H et al. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ. Res.83(1), 50–59 (1998).
   PubMed Web of Science ®Google Scholar
• Duerr RL, McKirnan MD, Gim RD, Clark RG, Chien KR, Ross J. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation93(12), 2188–2196 (1996).
   PubMed Web of Science ®Google Scholar
• Lee WL, Chen JW, Ting CT, Lin SJ, Wang PH. Changes of the insulin-like growth factor I system during acute myocardial infarction: implications on left ventricular remodeling. J. Clin. Endocrinol. Metab.84(5), 1575–1581 (1999).
   PubMed Web of Science ®Google Scholar
• Wang PH. Roads to survival: insulin-like growth factor-1 signaling pathways in cardiac muscle. Circ. Res.88(6), 552–554 (2001).
   PubMed Web of Science ®Google Scholar
• Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc. Natl Acad. Sci. USA92(17), 8031–8035 (1995).
   PubMed Web of Science ®Google Scholar
• Friehs I, Stamm C, Cao-Danh H, McGowan FX, del Nido PJ. Insulin-like growth factor-1 improves postischemic recovery in hypertrophied hearts. Ann. Thorac. Surg.72(5), 1650–1656 (2001).
   PubMed Web of Science ®Google Scholar
• Otani H, Yamamura T, Nakao Y et al. Insulin-like growth factor-I improves recovery of cardiac performance during reperfusion in isolated rat heart by a wortmannin-sensitive mechanism. J. Cardiovasc. Pharmacol.35(2), 275–281 (2000).
   PubMed Web of Science ®Google Scholar
• Wu W, Lee WL, Wu YY et al. Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J. Biol. Chem.275(51), 40113–40119 (2000).
   PubMed Web of Science ®Google Scholar
• Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitroand protects against ischemia–reperfusion injury in mouse heart. Circulation101(6), 660–667 (2000).
   PubMed Web of Science ®Google Scholar
• Parrizas M, Saltiel AR, LeRoith D. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3´-kinase and mitogen-activated protein kinase pathways. J. Biol. Chem.272(1), 154–161 (1997).
   PubMed Web of Science ®Google Scholar
• Urbanek K, Rota M, Cascapera S et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res.97(7), 663–673 (2005).
   PubMed Web of Science ®Google Scholar
• Vasan RS, Sullivan LM, D’Agostino RB et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann. Intern. Med.139(8), 642–648 (2003).
   PubMed Web of Science ®Google Scholar
• Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J. Mol. Cell Cardiol.31(11), 2049–2061 (1999).
   PubMed Web of Science ®Google Scholar
• Anker SD, Volterrani M, Pflaum CD et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J. Am. Coll. Cardiol.38(2), 443–452 (2001).
   PubMed Web of Science ®Google Scholar
• Niebauer J, Pflaum CD, Clark AL et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J. Am. Coll. Cardiol.32(2), 393–397 (1998).
   PubMed Web of Science ®Google Scholar
• Musaro A, Giacinti C, Borsellino G et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc. Natl Acad. Sci. USA101(5), 1206–1210 (2004).
   PubMed Web of Science ®Google Scholar
• von Lewinski D, Voss K, Hülsmann S, Kögler H, Pieske B. Insulin-like growth factor-1 exerts Ca2+-dependent positive inotropic effects in failing human myocardium. Circ. Res.92(2), 169–176 (2003).
   PubMed Web of Science ®Google Scholar
• Donath MY, Sütsch G, Yan XW et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J. Clin. Endocrinol. Metab.83(9), 3177–3183 (1998).
   PubMed Web of Science ®Google Scholar
• Osterziel KJ, Blum WF, Strohm O, Dietz R. The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration. J. Clin. Endocrinol. Metab.85(4), 1533–1539 (2000).
   PubMed Web of Science ®Google Scholar
• Napoli R, Guardasole V, Angelini V et al. Acute effects of growth hormone on vascular function in human subjects. J. Clin. Endocrinol. Metab.88(6), 2817–2820 (2003).
   PubMedGoogle Scholar
• Volterrani M, Desenzani P, Lorusso R, d’Aloia A, Manelli F, Giustina A. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet349(9058), 1067–1068 (1997).
   PubMed Web of Science ®Google Scholar
• Fazio S, Sabatini D, Capaldo B et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med.334(13), 809–814 (1996).
   PubMed Web of Science ®Google Scholar
• Jose VJ, Zechariah TU, George P, Jonathan V. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Indian Heart J.51(2), 183–185 (1999).
   PubMedGoogle Scholar
• Perrot A, Ranke MB, Dietz R, Osterziel KJ. Growth hormone treatment in dilated cardiomyopathy. J. Card. Surg.16(2), 127–131 (2001).
   PubMed Web of Science ®Google Scholar
• Frustaci A, Gentiloni N, Russo MA. Growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med.335(9), 672–673 (1996).
   PubMedGoogle Scholar
• Acevedo M, Corbalan R, Chamorro G et al. Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status. Int. J. Cardiol.87(2–3), 185–191 (2003).
   PubMed Web of Science ®Google Scholar
• Isgaard J, Bergh CH, Caidahl K, Lomsky M, Hjalmarson A, Bengtsson BA. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J.19(11), 1704–1711 (1998).
   PubMed Web of Science ®Google Scholar
• Spallarossa P, Rossettin P, Minuto F et al. Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Am. J. Cardiol.84(4), 430–433 (1999).
   PubMed Web of Science ®Google Scholar
• Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J. Clin. Endocrinol. Metab.92(1), 180–185 (2007).
   PubMedGoogle Scholar
• Bates AS, VantHoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab.81(3), 1169–1172 (1996).
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK et al. Association between premature mortality and hypopituitarism. Lancet357(9254), 425–431 (2001).
   PubMed Web of Science ®Google Scholar
• Rosen T, Bengtsson BA. Premature mortality due to cardiovascular-disease in hypopituitarism. Lancet336(8710), 285–288 (1990).
   PubMed Web of Science ®Google Scholar
• Elhadd TA, Abdu TAM, Clayton R. Hypopituitarism and atherosclerosis. Ann. Med.33(7), 477–485 (2001).
   PubMedGoogle Scholar
• Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab.89(5), 2192–2199 (2004).
   PubMed Web of Science ®Google Scholar
• Yuen KC, Frystyk J, White DK et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin. Endocrinol. (Oxf.)63(4), 428–436 (2005).
   PubMed Web of Science ®Google Scholar
• Capaldo B, Guardasole V, Pardo F et al. Abnormal vascular reactivity in growth hormone deficiency. Circulation103(4), 520–524 (2001).
   PubMed Web of Science ®Google Scholar
• Amato G, Carella C, Fazio S et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab.77(6), 1671–1676 (1993).
   PubMed Web of Science ®Google Scholar
• Longobardi S, Cuocolo A, Merola B et al. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin. Endocrinol. (Oxf.)48(2), 137–143 (1998).
   PubMed Web of Science ®Google Scholar
• Merola B, Cittadini A, Colao A et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J. Clin. Endocrinol. Metab.77(6), 1658–1661 (1993).
   PubMed Web of Science ®Google Scholar
• Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation108(21), 2648–2652 (2003).
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Biller BMK, Llevadot J et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency – a randomized, controlled clinical trial. Ann. Intern. Med.133(2), 111–122 (2000).
   PubMed Web of Science ®Google Scholar
• Klibanski A. Growth hormone and cardiovascular risk markers. Growth Horm. IGF Res.13, S109–S115 (2003).
   Google Scholar
• Kalina-Faska B, Kalina M, Koehler B. Effects of recombinant growth hormone therapy on thyroid hormone concentrations. Int. J. Clin. Pharmacol. Ther.42(1), 30–34 (2004).
   PubMedGoogle Scholar
• Agha A , Monson JP. Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis. Clin. Endocrinol.66(4), 459–465 (2007).
   PubMed Web of Science ®Google Scholar
• Verhelst J, Abs R. Long-term growth hormone replacement therapy in hypopituitary adults. Drugs62(16), 2399–2412 (2002).
   PubMedGoogle Scholar
• Fein FS. Diabetic cardiomyopathy. Diabetes Care13(11), 1169–1179 (1990).
   PubMedGoogle Scholar
• Bell D. Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care26(8), 2433–2441 (2003).
   PubMed Web of Science ®Google Scholar
• Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestril R, Wang PH. Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J. Mol. Cell. Cardiol.35(9), 1135–1143 (2003).
   PubMed Web of Science ®Google Scholar
• Fazio S, Palmieri EA, Biondi B, Cittadini A, Saccá L. The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence. Eur. J. Endocrinol.142(3), 211–216 (2000).
   PubMedGoogle Scholar
• Shan YX, Yang TL, Mestril R, Wang PH. Hsp10 and Hsp60 suppress ubiquitination of insulin-like growth factor-1 receptor and augment insulin-like growth factor-1 receptor signaling in cardiac muscle: implications on decreased myocardial protection in diabetic cardiomyopathy. J. Biol. Chem.278(46), 45492–45498 (2003).
   PubMedGoogle Scholar
• Schafler AE, Kirmanoglou K, Balbach J, Pecher P, Hannekum A, Schumacher B. The expression of heat shock protein 60 in myocardium of patients with chronic atrial fibrillation. Basic Res.Cardiol.97(3), 258–261 (2002).
   PubMedGoogle Scholar
• Lin KM, Lin B, Lian IY, Mestril R, Scheffler IE, Dillmann WH. Combined and individual mitochondrial HSP60 and HSP10 expression in cardiac myocytes protects mitochondrial function and prevents apoptotic cell deaths induced by simulated ischemia-reoxygenation. Circulation103(13), 1787–1792 (2001).
   PubMed Web of Science ®Google Scholar
• Chen HS, Shan YX, Yang TL et al. Insulin deficiency downregulated heat shock protein 60 and IGF-1 receptor signalling in diabetic myocardium. Diabetes54(1), 175–181 (2005).
   PubMedGoogle Scholar
• Lai HC, Liu TJ, Ting CT et al. Regulation of IGF-I receptor signalling in diabetic cardiac muscle: dysregulation of cytosolic and mitochondria HSP60. Am. J. Physiol. Endocrinol. Metab.292(1), E292–E297 (2007).
   PubMed Web of Science ®Google Scholar
• Lowell B, Shulman G. Mitochondrial dysfunction and Type 2 diabetes. Science307(5708), 384–387 (2005).
   PubMed Web of Science ®Google Scholar
• Dann SG, Selvaraj A, Thomas G. mTOR complex1–S6K1 signalling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med.13, 252–259 (2007).
   PubMed Web of Science ®Google Scholar
• Kaspar BK, Lladó J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science301(5634), 839–842 (2003).
   PubMed Web of Science ®Google Scholar
• Chao W, Matsui T, Novikov MS et al. Strategic advantages of insulin-like growth factor-I expression for cardioprotection. J. Gene Med.5(4), 277–286 (2003).
   PubMed Web of Science ®Google Scholar
• Slieker LJ. Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF1 receptor more than for the insulin receptor. Diabetol.40, S54–S61 (1997).
   PubMed Web of Science ®Google Scholar
• Hua QX. Mini-proinsulin and mini-IGF1: homologous protein sequences encoding non-homologous structures. J. Mol. Biol.277, 103–118 (1998).
   PubMedGoogle Scholar
• Pell JM, Hill RA, Stewart CE, Weston CR, Flick-Smith HC. Enhancement of insulin-like growth factor I activity by novel antisera: potential structure/function interactions. Endocrinology141(2), 741–751 (2000).
   Google Scholar
• Fan W. Insulin-like growth factor 1/insulin signalling activates androgen signalling through direct interactions of Foxo1 with androgen receptor. J. Biol. Chem.282, 7329–7338 (2007).
   PubMed Web of Science ®Google Scholar
• Elliot SJ. Smoking induces glomerulosclerosis in aging oestrogen-deficient mice through crosstalk between TGF-β and IGF1 signalling pathways. J. Am. Soc. Nephrol.17, 3315–3324 (2006).
   PubMedGoogle Scholar
• Sisci D, Surmacz E. Crosstalk between IGF signalling and steroid hormone receptors in breast cancer. Curr. Pharm. Des.13, 705–717 (2007).
   PubMedGoogle Scholar